Page 210 - Eceptor News Today

A research group of the Department of Pharmacy and Biotechnology of the University of Bologna analyzed more than one million SARS-CoV-2 genome sequences.

A new preprint research paper posted to the medRxiv* server points to mast cells as major culprits in the etiology of severe and critical COVID-19. This could suggest suitable therapeutic and preventive interventions to reduce the morbidity and mortality of this viral illness.

New technology predicts effectiveness of chemotherapy after one treatment While early detection of breast cancer is critical, early prediction of how well the neoadjuvant chemotherapy treatment before surgery is working also may provide a window of opportunity when treatment could be altered and have a big impact on the patients quality of life. An interdisciplinary team of researchers at Washington University in St. Louis has found that combining data from tumor biomarkers, ultrasound, and ult...

Researchers scour what is known to come up with a hypothesis of why blood clots can be a major problem in COVID-19

Following the Food and Drug Administration's approval, UC San Diego Health is the first designated medical center in San Diego certified to offer a new immunotherapy treatment of multiple myeloma outside of a clinical trial.

A preprint paper uploaded to the bioRxiv* server shows how combining drugs targeting different entry factors of the host cell may prevent infection by the virus.

Study brings to light the role of a cellular protein in COVID-19 infections Jun 4 2021 Angiotensin-converting enzyme 2 (ACE2), a protein found on the surface of lung cells, facilitates the entry of the novel coronavirus into host cells. While targeting ACE2 can be a potential treatment against COVID-19, there is still some ambiguity about how ACE2 works. To this end, researchers in UAE dug deeper into ACE2 and its role in COVID-19 infections, in a comprehensive review. Targeting the sub-cellula...

Updated results from a dataset of 43 patients showed durable responses and stable disease greater than six months with inupadenant monotherapy in five patients with advanced solid tumors, including

A new medRxiv* preprint reports the immunomodulatory effect of the E484K mutation newly acquired by the United Kingdom (U.K.) variant.

A new study published in the journal Stem Cell Reports by University of Alberta researchers is shedding light on why many COVID-19 patients, even those not in hospital, are suffering from hypoxia--a potentially dangerous condition in which there is decreased oxygenation in the body's tissues.